Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Filtros aplicados

Base de dados
Intervalo de ano de publicação
1.
West Indian med. j ; 33(2): 106-16, June 1984.
Artigo em Inglês | MedCarib | ID: med-11485

RESUMO

This work was designed to evaluate, in conjunction with certain dopamine agonists, the effects of disruption of the mesolimbic system on spontaneous motor activity and stereotype. The results indicated that lesions to the nucleus accumbens produced increments in motor activity that were exacerbated by amphetamine (5.0 mg/kg). Administration of apomorphine (1.0 mg.kg) produced similar results but was not as effective as amphetamine in inducing motor dysfunction. The relevance of these findings to psychopathology and motor disorders is discussed, with implications for public health policy (AU)


Assuntos
21003 , Humanos , Masculino , Ratos , Dopamina/antagonistas & inibidores , Atividade Motora/efeitos dos fármacos , Núcleo Accumbens/fisiologia , Núcleos Septais/fisiologia , Apomorfina/farmacologia , Dextroanfetamina/farmacologia , Núcleo Accumbens/efeitos dos fármacos , Ratos Endogâmicos , Esquizofrenia/etiologia
2.
West Indian med. j ; 31(3): 138-48, Sept. 1982.
Artigo em Inglês | MedCarib | ID: med-11379

RESUMO

This work was conducted to evaluate the effects of bilateral lesion of the globus pallidus on spontaneous motor behaviour and drug-induced stereotypy. The evidence suggests that the pallidus is necessary for the expression of normal motor behaviour. Bilateral lesioned rats manifested hypoactivity. This hypoactivity or response depression was counteracted by low and high doses of amphetamine. Apomorphime (1.0 mg/kg) induced a normalizing effect on spontaneous motor activity in lesioned rats. However this higher dose of apomorphine induced marked stereotypic activity in lesioned rats. The results of this work raise important implications for certain motor disorders and the psychoses. (AU)


Assuntos
21003 , Humanos , Masculino , Ratos , Corpo Estriado/fisiologia , Dextroanfetamina/administração & dosagem , Globo Pálido/fisiologia , Atividade Motora/fisiologia , Comportamento Estereotipado/fisiologia , Apomorfina/administração & dosagem , Ratos Endogâmicos
3.
Kingston; ; Feb. 1978. 158 p. tab.
Tese em Inglês | MedCarib | ID: med-13728

RESUMO

The cardinal features of the hyperkinetic child syndrome is excessive non-goal directed motor overactivity and impulsivity. Although hyperactive children constitute a small part of their age group, 4 percent - Steward et al 1966, their effects on peers and demands on teachers and parents are far out of proportion to their number. In addition, the linkage between hyperkinesia and adult psychopathology (like-emotional immaturity, inability to attain goals, feelings of hopelessness and poor self image) has been inferred from longitudinal, retrospective and family studies (Arnold et al 1972, Huessy 1974, Robins 1966). The present drugs of choice for the treatment of hyperkinesia (central nervous system stimulants like methylphenidate and d-amphetamine), have serious side effects and long periods of administration are known to cause psychosis (Laufer and Denhoff 1957). In the light of the above problems, fundamental research aimed at elucidating the biochemical determinants of hyperkinesia would be very useful, as this might result in better pharmaco-therapy for the syndrome. However, caution should be excercised in extrapolating results from animal to man. Since a functional interrelationship exists between dopaminergic and cholinergic systems (Sethy and Van Woert 1974), in the extrapyramidal system (this is important for the control of motor activity in man and other mammals), it was therefore hypothesized that motor hyperactivity could be due to a cholinergic inbalance in the brain. Rats' motor activity would seem a reasonable model for this study, as the main symptom of this syndrome is motor hyperactivity. Female rats (mean body weight 200 ñ 5G) were used for this study. Motor activity was measured with jiggle platforms which monitor the gross motor activity of the test animals as opposed to photoelectric activity cages which only measure animals locomotion. All drugs used for this study were injected intraperitoneally at a volume of 0.1ml, and the testing period for each rat was 60-min. Physostigmine at dose levels (0.01 - 0.18mg/kg) significantly increased rats motor activity as compared to saline controls. This increase in motor activity was also obtained when physostigmine at 0.05mg/kg was injected daily for four days. Atropine sulphate (5 and 10 mg/kg) attentuated the physostigmine induced increase in motor activity. However, the physostigmine induced excitation was potentiated by d-amphetamine at 1, 2 and 4mg/kg. These effects occurred whether physostigmine was injected before or after atropine and d-amphetamine. The effect of physostigmine on motor activity is central as neostigmine did not induce any stimulation of rats' motor activity. In addition reserpine, phenobarbitone, haloperidol and practocol (a beta-adrenergic blocking drug), attentuated the physostigmine-induced increase in motor activity, while phentolamine and tranylcypromine (MAO Inhibitor) did not affect the physostigmine-induced excitation. These results are discussed in conjunction with the findings of other workers and is concluded that: (i) increasing the acetylcholine level of the rats brain with an anticholinesterase (physostigmine) induces motor hyperactivity: (ii) anticholinergics and neuroleptics are capable of attenuating this physostigmine-induced motor hyperactivity. (iii) the fact that d-amphetamine potentiated the physostigmine-induced motor hyperactivity may exlain the observation that following d-amphetamine or methylphenidate treatment, some hyperkinetic children (30 percent) manifest a worsening of their symptoms. (Satterfield et al 1972). If in some subtypes of hyperkinetics, a cholinergic dysfunction is present, then it follows on the basis of the present study that d-amphetamine will excercebate their condition, while anticholinergics might be useful therapy (AU)


Assuntos
Humanos , Criança , Ratos , Feminino , Hipercinese/etiologia , Neurofarmacologia/métodos , Hipercinese/induzido quimicamente , Atividade Motora/efeitos dos fármacos , Fisostigmina/farmacologia , Parassimpatolíticos/farmacologia , Antipsicóticos/farmacologia , Dextroanfetamina/farmacologia , Sistema Nervoso/efeitos dos fármacos
4.
Psychopharmacology ; 54: 25-30, 1977.
Artigo em Inglês | MedCarib | ID: med-12149

RESUMO

Intraperitoneal administration of physostigmine (0.025 to 0.18 mg/kg) to rats resulted in dignificant increases in motor activity as measured with jiggle platforms. Doses of physostigmine 0.2 mg/kg or more decreased motor activity. The physostigmine-induced hyperactivity was attenuated by atropine (5 mg/kg) given before or after physostigmine (0.05 mg/kg). On the contrary, d-amphetamine (2 mg/kg), given before or after, significantly potentiated the physostigmine-induced increase in motor activity. The relevance of the cholinergic system in mediating hyperactive behaviour in children is discussed. (AU)


Assuntos
Ratos , 21003 , Feminino , Atropina/farmacocinética , Dextroanfetamina/farmacocinética , Atividade Motora/efeitos dos fármacos , Interações Medicamentosas , Neostigmina/farmacocinética , Fisostigmina/farmacocinética , Fatores de Tempo
5.
Neuropharmacology ; 15(5): 269-71, May 1976.
Artigo em Inglês | MedCarib | ID: med-5354

RESUMO

Rats that were treated with physostigmine (0.05 mg/kg) manifested marked hyperactive behaviour. A subsequent injection of dexamphetamine (2.0 mg/kg) did not antagonise the physostigmine-induced locomotor hyperactivity, whereas atropine (10 mg/kg) attenuated the hyperactive behaviour. Higher doses of physostigmine depressed the locomotory behaviour of rats. Carbachol and (ñ)-O-methyl-p-tyrosine did not significantly affect rats' locomotory behaviour. Implications of the results are discussed in terms of the aetiology of hyperkinesia (AU)


Assuntos
21003 , Ratos , Dextroanfetamina , Atividade Motora/efeitos dos fármacos , Fisostigmina , Carbacol , Interações Medicamentosas , Metiltirosinas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA